NVS’ LEE011 data impress in first-line HR+/HER2- breast cancer: http://finance.yahoo.com/news/novartis-challenges-pfizer-strong-breast-061501508.html http://finance.yahoo.com/news/novartis-breakthrough-therapy-lee011-ribociclib-120000970.html The main competition for LEE011 is PFE’s Ibrance.